University of Gothenburg
Checkpoint Immunotherapy Response Described in Tumors with Gene Fusion-Based Neoantigens
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.